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The primary aim of this study is to evaluate the evidence for antiplatelet therapy as secondary stroke prevention in patients with lacunar stroke. We performed a systematic review and pooled meta-analysis of randomized controlled trials.
Methods

Eligibility Criteria
We included randomized controlled trials that evaluated the use of antiplatelet therapy as secondary prevention after acute stroke. Among these trials, only those which reported outcomes separate for lacunar stroke were included. For certain trials, additional data were obtained via personal correspondence from the authors.
Outcomes
Primary outcome of interest was any stroke recurrence (ischemic or hemorrhagic). Secondary outcomes of interest were (1) recurrent ischemic stroke and (2) composite of any stroke, myocardial infarction, and death. We accepted composite outcomes as specified by trial investigators so long as strokes and deaths were captured in the composite end point.
Search Strategy
MEDLINE and Embase searches with no date limitations or language restrictions were conducted in December 2013 using the broad search terms as shown in Supplementary Data I in the online-only Data Supplement. Furthermore, we reviewed the bibliography of included trials, Cochrane Reviews, and the most recent review by the antithrombotic trialist collaboration for additional studies.
Study Selection and Data Extraction
Two reviewers (C.S. Kwok and A. Shoamanesh) considered all titles and abstracts retrieved from the search for potential eligibility. Where there was disagreement, study inclusion or exclusion was agreed upon by consensus with the other authors. Two reviewers (C.S. Kwok and H.C. Copley) independently extracted information on study design, participant characteristics, types of interventions, outcomes, results, and risk of bias onto a spreadsheet. The 2 extractions were compared and differences were resolved by consensus. Where there was uncertainty, journal authors were contacted for clarification.
Assessment of Risk of Bias
Two reviewers (C.S. Kwok and H.C. Copley) independently assessed the individual studies' risks of bias in accordance with the recommendations of the Cochrane Collaboration, which included baseline differences, blinding, lost to follow up, exposure and outcome ascertainment, and conflicts of interest. We planned to assess publication bias using funnel plots if there were >10 studies included in the meta-analysis, and there was no significant statistical heterogeneity. 6 
Statistical Analysis
Fixed effects meta-analysis of dichotomous events was performed using RevMan 5.3 (Nordic Cochrane Center, København, Denmark) to estimate pooled risk ratios (RRs). Statistical heterogeneity was assessed using I 2 statistic, with values of 30% to 60% representing a moderate level of heterogeneity. 7 We performed secondary analysis considering only ischemic stroke as the outcome. Annual event rates per 100 patient years of follow-up were estimated by adjusting the studies event rate according to the trial's mean follow-up duration.
Results
We included a total of 17 randomized trials that included 42 234 participants with lacunar stroke treated with antiplatelet therapy (mono or dual) or placebo. 22 ) in our pooled analysis. IST's composite outcome of death and dependency did not match our criteria, and TRA 2P-TIMI50 did not provide number of events. Novel less-established agents were excluded from the analysis in an attempt to reduce the level heterogeneity between the different agents' mechanisms of action, but their results are reported separately (Saprogelate [S-ACCESS] 17 and Terutroban [PERFORM] 21 trials). The process of study selection is shown in Figure I in the online-only Data Supplement. Table shows the summary characteristics of the study populations of included studies. Of these, 14 were double-blind randomized trials. The mean age was 64 years, and 65% of participants were male across 16 studies; one study (IST) reported 61% of participants >70 years of age and one study (CSPS2 [Cilostazol Stroke Prevention Study]) 18 did not report the number of male and female participants. All the studies included participants with suspected ischemic stroke or transient ischemic attack, and neuroimaging was performed to confirm diagnosis in all but one study (CATS [Canadian American Ticlopidine Study]), 9 which relied on neurological evaluation for diagnosis. Only 6 of the studies formally defined lacunar stroke using criteria, such as the TOAST Criteria, modified Fisher criteria, or other predefined criteria, and only 1 used magnetic resonance imaging to verify the diagnosis of lacunar stroke. 3 Table I in the online-only Data Supplement shows the quality assessment of the studies included. Sequence generation of randomization was described in 10 studies and allocation concealment was described in 13 studies. Fourteen trials were double blind trials, and some means to assess treatment exposure or compliance was considered in 8 trials. All but one study had some form of outcome ascertainment, and 4 studies had unclear participant lost to follow-up.
The treatments received, crude events rate, outcomes, and results are shown in Table II in the online-only Data Supplement. The follow-up of the studies ranged from 4 weeks to 3.5 years.
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April 2015 Overall, the meta-analysis shows no significant advantage of other single agents above aspirin alone. These analyses are shown in Figure 2A and 2B. Two trials, PERFORM 21 and S-ACCESS, 17 evaluating terutroban and sarpogrelate also found no significant benefit above aspirin alone (terutroban HR 0.90, 0.62-1.31; sarpogrelate HR 1.31, 0.84-2.04).
Dual Antiplatelet Therapy Versus Aspirin Alone
The results of DAPT versus aspirin are shown in Figure 3 . Overall, DAPT may possibly have a modest advantage over aspirin, but this is driven mainly by the aspirin/dipyridamole data from ESPS-2. 19 The pooled risk ratio for any stroke, ischemic stroke, and the composite outcome were RR 0.83, 0.68 to 1.00; RR 0.80, 0.62 to 1.02; and RR 0.95,0.85 to 1.07, respectively.
Dipyridamole/Aspirin, Clopidogrel/Aspirin, and Ticlopidine Versus Clopidogrel Alone
We observed no significant advantage of DAPT versus clopidogrel or ticlopidine versus clopidogrel. For this analysis, aspirin/dipyridamole did not seem to be superior to clopidogrel alone. Results are shown in Figure 4 . Finally, DAPT using vorapaxar in addition to aspirin or clopidogrel use showed no significant benefit on vascular end points (HR 0.99,0.75-1.31).
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Discussion
The current American Heart Association guidelines 24 state that 4 antiplatelet regimens (aspirin, clopidogrel, ticlopidine, or the combination of dipyridamole and aspirin) have been shown to reduce the risk of ischemic stroke after stroke or TIA. The guidelines further suggest that several factors should be considered, such as patient comorbidities, side effects, and costs, when choosing an agent at an individual level. Suitably, our findings suggest that antiplatelet monotherapy (ie, aspirin, dipyridamole, clopidogrel, cilostazol, and ticlopidine) should be recommended as secondary prevention of stroke among patients with lacunar stroke. Aspirin seems to be as good as any other antiplatelet agents and is likely the appropriate first line in most because it is less expensive and generally well tolerated, which may increase long-term adherence to therapy. 24 Cilostazol showed a nonsignificant trend in reducing strokes when compared with aspirin; however, further larger studies are needed to validate these findings and ensure generalizability to non-East Asian populations.
Unfortunately, in view of the limited number of studies which evaluate the role of DAPT, we are unable to separate out individual agents and maintain a meaningful pooled analysis. Accordingly, we identified substantial heterogeneity in the effects of DAPT, which vary depending on the choice of the combination and the comparator drugs. Only one trial shows DAPT to be favorable (ESPS-2), but the superiority of dipyridamole and aspirin was not replicated when clopidogrel was used as the control rather than aspirin. Moreover, long-term DAPT with clopidogrel/aspirin led to significantly higher rates of major bleeding in MATCH (Management of Atherothrombosis With Clopidogrel in High-Risk Patients) and all-cause mortality in SPS3. Therefore, current evidence does not justify the use of longterm DAPT in patient with lacunar stroke.
Our results are in line with those of the SPS3 trial regarding the lack of benefit from clopidogrel and aspirin therapy in lacunar stroke patients. We, however, did not notice 
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any significant increase in our composite outcome of any stroke, myocardial infarction, and death. Limited by the available published data, we were unable to consider mortality rates in isolation; however, long-term DAPT (mean 3.4 years) led to increased all-cause mortality (HR 1.52, 1.14-2.04, P=0.004) in comparison to monotherapy with aspirin within SPS3. 3 Our study has limitations. There were a limited number of trials, and there was insufficient data to investigate particular outcomes, such as hemorrhagic stroke or all-cause mortality in isolation. Additionally, lacunar stroke was defined in a heterogeneous manner among the trials, with only one study using a strict clinical criteria and magnetic resonance imaging verification of the infarct, 3 and we were unable to consider the effect-specific DAPT regimens in isolation. A final limitation is that our analysis is unable to account for possible differences in treatment-effects between the acute/semiacute phase after stroke and the chronic phase.
In conclusion, our results suggest that at present, antiplatelet monotherapy of the agents included in the trials should be indicated for secondary stroke prevention after a lacunar stroke. Furthermore, current data are insufficient to justify using one antiplatelet agent over another in this particular population.
67
63% Participants were aged ≥55 years, who had had an ischemic stroke or arterial retinal ischemic event >48 h and <3 months preceding inclusion or a TIA in the previous 8 days.
Ischemic stroke was confirmed by brain imaging.
Yes. Ischemic stroke was categorized into lacunar stroke based on prior defined criteria. 65 75% Participants were eligible for the trial if they experienced their first lacunar infarction within the preceding 7 days and were ≥45 years of age.
All registered patients had a brain CT and MRI to exclude hemorrhages and other causes.
Yes ESPRIT [9] Treatment allocation was by means of computer generated randomization codes stratified by hospital before the start of the trial.
Adequate allocation concealment with randomization by means of a telephone call, fax, or email to the central trial office.
Nonblinded.
30-325 mg ASA daily with or without 200 mg dipyridamole twice daily, exposure for duration of study; medication compliance asked a follow-up.
Ischemic stroke and all cardiac events (MI, sudden death and death from cardiac causes); 3 member committee audited outcome events and independently classified events.
3.5 years; 106 participants were lost to follow up, 554 discontinued treatment.
S-ACCESS [10]
Patients were randomly assigned according to an allocation table that was generated by using random numbers by a person who was not part of this study.
Adequate allocation concealment with web-based randomization. 2.5 years; 0.6% were lost to follow up in each arm.
CSPS2 [12]
The randomization table was generated with SAS and random allocation was done with a dynamic balancing method to minimize differences in the distribution of baseline variables between the two groups.
Adequate allocation concealment with remote randomization by contract research organisation at the registration centre. AAASPS [13] Patients were randomized using a algorithm using a length of block varying from 2 to 8 with a ratio of patients receiving ticlopidine to aspirin of 1:1.
Adequate allocation concealment with automated phone registration.
Doubleblind
650 mg ASA, 500 mg ticlopidine; exposure duration of study; ascertained by pill counting.
Any stroke; blinded adjudication committee.
1.54 years; 522 participants withdrew from study but all were included in analysis. SPS3 [14] Randomization assignments were Adequate allocation concealment Double-325 mg ASA daily with or Any stroke, ischemic 3.4 years; no loss to generated using a permuted-block design (variable block size).
using central web-based system. blind. without 75 mg clopidogrel daily; exposure for duration of study; adherence measured by pill count.
stroke, death and MI; ascertained by the blinded Events Adjudication Committee.
follow up.
PERFOR M [15]
The allocation sequence was generated by the sponsor through in-house application software. The randomization was balanced, nonadaptive, and stratified by country, with blocks of size four.
Adequate allocation concealment by a central interactive response system (telephone or internet). A blocked randomization procedure generated by a statistician was used by the central trial pharmacist randomized patients.
Adequate allocation concealment with randomization by central trial pharmacist who produced identical study kits. the patients who experienced an event, 27.3% (n=1639) died in hospital or within 7 days of discharge. The 30-day cumulative incidence of ischemic stroke among new users of warfarin was 0.5% (n=721), increasing to 2.0% (n=2,917) after 1 year, 2.7% (n=4067) after 2 years, and 4.0% (n=6006) after 5 years. The risk was highest during the first 30 days of warfarin therapy: 6.0% PPY (95% confidence interval, 5.5%-6.4%) versus 1.6% PPY (95% confidence interval, 1.5%-1.6%) during the remainder of the 5-year follow-up (Table 2; Figure) .
Crude 5-year rates of ischemic stroke increased significantly as CHADS 2 scores increased (P<0.0001; Table 2; Figure I in the online-only Data Supplement) and among those with a history of stroke (P<0.001; Table 2; Figure II in the onlineonly Data Supplement). A sensitivity analysis demonstrated no difference in stroke rates according to timing of warfarin initiation after atrial fibrillation diagnosis (Table 2 ). Relative to patients who did not experience a stroke, those who did were less likely to have received an international normalized ratio test in the preceding 14 days (Table II in the online-only Data Supplement). Few patients received heparin or antiplatelet therapy (Table 1) .
Discussion
In this population-based study, the rate of ischemic stroke in older patients with atrial fibrillation starting warfarin was significantly elevated during the first month of treatment. This early elevated risk increased with previous stroke history and higher baseline CHADS 2 score.
The overall 5-year risk of stroke observed in our study (1.8% PPY) is comparable with the annual incidence rate of 1.66% (95% confidence interval, 1.41%-1.91%) reported in a meta-analysis of 8 randomized controlled trials and an observational study by Azoulay et al, 3, 5 but higher than the rate of 1.17% PPY reported in another observational study of younger patients with lower CHADS 2 scores. 1 The explanation for our findings is likely multifactorial. The results may reflect the high-risk period after a transient ischemic attack, 6 and the time required to achieve therapeutic anticoagulation. Less frequent international normalized ratio testing may have been a contributor. More research is needed to elucidate whether a transient hypercoagulable state seen immediately after warfarin initiation explains our findings. 7 Our sensitivity CHADS 2 indicates score comprised of congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke; and CI, confidence interval.
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analysis stratifying patients by timing of warfarin initiation after atrial fibrillation diagnosis found similar stroke rates in both groups. This suggests our findings are not simply influenced by elevated rates of stroke after atrial fibrillation diagnosis, as has been previously reported. 8 Moreover, few patients received heparins or antiplatelet agents before initiating warfarin. Studies are needed to determine whether bridging therapy, antiplatelet therapy, or use of direct-acting anticoagulants mitigate this early increased stroke risk.
Strengths of this study include its large, populationbased sample and long follow-up. Limitations include our inability to assess the quality of anticoagulation. We also could not capture stroke events that did not result in hospitalization or some important risk factors for stroke, such as hypertension.
Conclusions
In this large, population-based cohort study of older patients with atrial fibrillation, we observed the highest rate of ischemic stroke in the first 30 days after warfarin initiation. Although this does not provide evidence of a causal link between warfarin initiation and stroke, the persistence of thromboembolic risk despite anticoagulation highlights the need for future research in this area. 
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